Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegcetacoplan in PNH Extension Study
NCT03531255Phase 3Completed
- Sponsor
- Apellis Pharmaceuticals
- Start
- Aug 2018
- Primary completion
- Sep 2025
- Modality
- PEGylated Peptides
- Countries
- 21
01
Overview
A Phase 3 trial of pegcetacoplan in paroxysmal nocturnal hemoglobinuria (PNH), sponsored by Apellis Pharmaceuticals. Started Aug 2018; status: completed.
02
Drugs
pegcetacoplan
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on NCT03531255.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03531255.